Venaxis kurz vor der FDA Zulassung
Seite 1 von 2 Neuester Beitrag: 25.04.21 01:39 | ||||
Eröffnet am: | 21.04.14 00:48 | von: usambara | Anzahl Beiträge: | 34 |
Neuester Beitrag: | 25.04.21 01:39 | von: Leahjssya | Leser gesamt: | 11.208 |
Forum: | Hot-Stocks | Leser heute: | 15 | |
Bewertet mit: | ||||
Seite: < 1 | 2 > |
Ich denke schon denn die Insiderkäufe sprechen eine deutlich Sprache.
http://secfilings.nasdaq.com/...4&RcvdDate=4%2F17%2F2014&pdf=
A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com/webcast/. Participants and investors may also access the conference call by dialing 1-888-455-2260 (U.S.) or 1-719-457-2645 (Toll - International).
A replay of the call will be available approximately an hour after the end of the conference call on the Company's website. To access the webcast, please visit the investor relations section of the Venaxis website at www.venaxis.com/webcast/.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low probability for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While the FDA clearance process and status is being evaluated, a limited commercial launch for the APPY1 Test is advancing in select European countries. For more information, visit www.venaxis.com.
http://www.prnewswire.com/news-releases/...ness-update-300061093.html
viel glück!
Bei Zulassung sind nach meiner Einschätzung 5,--$ drin!
Kommen dann die Umsätze muss das Kursziel nach oben revidiert werden aber erst geht es zu neuen Anlauf - ab sofort könnten zu dem Thema täglich News kommen.
Fait vos jeux - rien ne vas plus :-)